Life Science News

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for operational health, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC"), a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly-traded companies in the United States.

The Company's shares will continue to trade in the USA, under the ticker BLMHF on the OTCQB Market. DTC eligibility reduces costs and accelerates the settlement process for investors and brokers allowing the Company's common shares to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.

"This is an important step in making Bloom's shares accessible to the widest audience possible, as DTC eligibility allows Bloom's existing U.S investors to benefit from electronic clearing and settlement of the Company's shares within the United States," said Andrew Morton, CEO of Bloom.

About Bloom Health Partners Inc.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: investors@bloomhealthpartners.com

On behalf of the board of directors,

Bloom Health Partners Inc.

Andrew Morton, Chief Executive Officer

Forward-Looking Statements

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/110598

News Provided by Newsfile via QuoteMedia

BLMH:CNX
Bloom Health Partners

Bloom Health Partners


Keep reading...Show less
Bloom Health Partners Invited to U.K. MedTech Trade Mission

Bloom Health Partners Invited to U.K. MedTech Trade Mission

British Columbia government selects Bloom, a leader in Workplace Health-Tech, to join event designed to open doors, facilitate partnerships, expand business

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for operational health, announced it has been asked by the British Columbia Ministry of Jobs, Economic Recovery & Innovation to join a government-supported virtual trade mission to the United Kingdom.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Extends Contract with State of Texas for K-12 Schools

Bloom Health Partners Extends Contract with State of Texas for K-12 Schools

Program for K-12 schools for lab-based testing along with supply and management of rapid tests is extended through the 2022-2023 school year in Texas.

 Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company") a global platform for operational health, announces that it has been awarded an extension of its state-wide contract for testing in Texas for K-12 schools to the end of the 2022-2023 school year. Bloom's program with schools in Texas, announced in January, includes both rapid and lab testing that covers the needs of schools as they plan for waves and variants associated with the pandemic. As previously announced, Bloom will conduct PCR testing in the Company's Dallas-based laboratory. Rapid tests will continue to be supplied to schools, with results data managed on Bloom's cloud data platform.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Appoints Seasoned Healthcare Executive as Chief Operations Officer--Rosemary Elliston

Bloom Health Partners Appoints Seasoned Healthcare Executive as Chief Operations Officer--Rosemary Elliston

Clinical, technology and operations leadership veteran with a proven track record brings experience to Bloom's Operational Health and Health-Tech strategy

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for healthcare security, is pleased to announce the appointment of Rosemary Elliston as Chief Operations Officer (COO).

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Completes Fiscal Q1 2022 with $5.8M in Revenue and Maintains Guidance for Full Fiscal Year

Bloom Health Partners Completes Fiscal Q1 2022 with $5.8M in Revenue and Maintains Guidance for Full Fiscal Year

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces Q1 Fiscal 2022 revenues of C$5.8M for the period ended December 31st, 2021.

Bloom completed Fiscal Q1 2022 with revenue of C$5.8M and C$5.1M in cash. The Company completed this quarter with a loss from operations of C$1M, which is largely attributed to an investment in expansion and a lower revenue quarter due to cyclical factors. The full report and financial statements are available under the profile for the Company on www.sedar.com.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom logo

Bloom Health Partners Announces Health-Tech Software Platform

"Bloom Shield" Operational Health-Tech Cloud Software Platform Manages Employee Health for Workplaces and Large Organizations

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for Operation Health, is proud to announce "Bloom Shield" cloud software as a part of the company's platform of services for Fortune 500 organizations, Schools and significant Film and TV productions.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2022, which ended on Friday, April 29, 2022 .

Medtronic will host a video webcast at 7:00 a.m. CDT on Thursday , May 26, 2022, to discuss financial results for its fourth quarter and full fiscal year 2022. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

  • Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life
  • Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies
  • One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis

Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transcatheter aortic valve implantation (TAVI) system. The company also showcased new data for MitraClip™ and Amplatzer™ Amulet™, two key components of the company's industry-leading structural heart portfolio.

All data were presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held in Paris from May 17-20, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022.

About Thermo Fisher Scientific

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Premier Health Reports FY2022 Second Quarter Results

Premier Health Reports FY2022 Second Quarter Results

Premier Health of America Inc. (TSXV: PHA ) (the " Corporation "), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and Management Discussion and Analysis for its second quarter ended March 31, 2022.

Summary

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU ® Research Posters Will Be Presented

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, today announced seven posters on behalf of XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), will be shared at Digestive Disease Week® (DDW) 2022 which is being held virtually and in-person in San Diego, Calif. from May 21-24, 2022 . The posters will be accessible on DDW's ePoster's website beginning Saturday, May 21, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×